Anixa Biosciences Inc
ANIX
Company Profile
Business description
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Contact
3150 Almaden Expressway
Suite 250
San JoseCA95118
USAT: +1 408 708-9808
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2025
Employees
5
Stocks News & Analysis
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
stocks
These 2 ASX stocks look materially overvalued after earnings
Both of these moated companies annouced solid enough results, but our analysts continue to think the shares are too expensive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,804.20 | 4.60 | 0.05% |
| CAC 40 | 8,146.98 | 104.79 | 1.30% |
| DAX 40 | 22,486.44 | 338.41 | 1.53% |
| Dow JONES (US) | 44,368.56 | 225.09 | -0.50% |
| FTSE 100 | 8,762.46 | 44.98 | -0.51% |
| HKSE | 21,814.37 | 43.55 | -0.20% |
| NASDAQ | 19,649.95 | 6.10 | 0.03% |
| Nikkei 225 | 39,461.47 | 497.77 | 1.28% |
| NZX 50 Index | 12,905.98 | 7.97 | -0.06% |
| S&P 500 | 6,051.97 | 16.53 | -0.27% |
| S&P/ASX 200 | 8,540.00 | 4.70 | 0.06% |
| SSE Composite Index | 3,332.48 | 13.90 | -0.42% |